Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615763 | 1.00 | P2RX3 (0.32) | P2RX3P2RX7DRD4EZH2HTR2A | |
| SCHEMBL14007686 | 0.85 | HTR2A (0.32) | P2RX7DRD4EZH2HTR2AGRM2 | |
| SCHEMBL1338248 | 0.81 | SIGMAR1 (0.33) | P2RX7DRD4HTR2AGRM2 | |
| SCHEMBL1336152 | 0.80 | OPRK1 (0.36) | P2RX7DRD4EZH2HTR2AGRM2 | |
| SCHEMBL1337786 | 0.80 | MAOB (0.36) | P2RX7EZH2 | |
| SCHEMBL14034677 | 0.77 | DOCK5 (0.30) | — | |
| SCHEMBL2028051 | 0.77 | WDR5 (0.35) | P2RX7DRD4EZH2HTR2AGRM2 | |
| SCHEMBL1337247 | 0.76 | GRM2 (0.33) | DRD4HTR2AGRM2 | |
| SCHEMBL12129232 | 0.76 | GRM2 (0.33) | DRD4HTR2AGRM2 | |
| SCHEMBL3490121 | 0.76 | GRM2 (0.33) | DRD4HTR2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280945-A1 | Crystalline forms of an HIV integrase inhibitor | TYMP, SAMHD1, ACIN1 | P2RX3 4841/4885P2RX7 4649/4885DRD4 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.